TrialID,Phase,phase_clean,manual,study_arm,url,Scientific_title,Conditions,Date_enrollment_format,control_arm,randomisation,blinding,subject_blind,caregiver_blind,investigator_blind,outcome_blind,analyst_blind,prospective,Source_registry,region_Africa,region_N_America,region_L_America,region_Asia,region_Europe,region_Oceania,multicentre,primary_purpose,sponsor_type,sample_size,vaccine,conventional,traditional,Bridging_flag,Study_design,Day_inferred,Date_registration_format,Public_title,Countries,Primary_sponsor,Interventions
EUCTR2006-005558-63-IT,NULL,Unreported,Phase 3,im,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005558-63,"A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadjuvanted inactivated subunit influenza vaccine, when administered to adults affected by chronic diseases",Influenza <br>MedDRA version: 18.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],2006-11-28,Yes,Yes,Yes,NA,NA,NA,NA,NA,NA,EUCTR,No,No,No,No,Yes,No,No,NA,industry,NA,NA,NA,NA,NCT00519064,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: noParallel group: noCross over: noOther: yesOther trial design description: observer-blindIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2",FALSE,2016-03-24,"A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadjuvanted inactivated subunit influenza vaccine, when administered to adults affected by chronic diseases",Italy,Novartis Vaccines and Diagnostics S.r.l.,<br>Trade Name: FLUAD<br>Product Name: FLUAD<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br><br>Trade Name: Agrippal<br>Product Name: Agrippal<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br><br>
